vorinostat has been researched along with Diffuse Large B-Cell Lymphoma in 17 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A panel of rituximab-chemotherapy-sensitive (RSCL) and rituximab-chemotherapy-resistant cell lines (RRCL) and primary tumor cells isolated from relapsed/refractory B cell lymphoma patients were exposed to escalating doses of vorinostat." | 7.83 | Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. ( Czuczman, MS; Gu, JJ; Guo, Y; Hernandez-Ilizaliturri, FJ; Mavis, C; Xue, K; Zhang, Q, 2016) |
| " S0806 was a single arm phase I/II trial of vorinostat given at 400 mg po daily on days 1-9 (subsequently amended to days 1-5 due to toxicity), combined with R-CHOP given on day 3 of a 21-day cycle for 8 cycles, with primary phase II endpoint of 2-year progression free survival (PFS)." | 6.87 | A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. ( Bane, CL; Barr, PM; Fisher, RI; Friedberg, JW; LeBlanc, M; Li, H; Persky, DO; Popplewell, LL; Rimsza, LM; Smith, SM; Von Gehr, A, 2018) |
| "Vorinostat (400 mg) was administered orally on days 1 to 5 and 8 to 12 before bortezomib (1." | 6.87 | A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. ( Badros, AZ; Baz, R; Bose, P; Coppola, D; Flowers, C; Grant, S; Holkova, B; Kimball, A; Kmieciak, M; Lin, HY; Morgan, D; Parekh, S; Perkins, EB; Reich, RR; Richards, KL; Roberts, JD; Ruan, J; Sankala, H; Shafer, D; Shea, T; Shrader, E; Sokol, L; Strair, R; Sullivan, D; Tombes, MB; Yazbeck, V; Zhao, X, 2018) |
| "The standard treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in frail elderly patients has not been established." | 6.80 | Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation. ( Cella, D; Drullinsky, PR; Elstrom, R; Gerecitano, JF; Hamilton, AM; Hamlin, PA; Lia Palomba, M; Matasar, MJ; Noy, A; Straus, DJ; Wegner, B; Wortman, K; Zelenetz, AD, 2015) |
| "Cladribine is a purine nucleoside analog used to treat B-cell chronic lymphocytic leukemia and hairy cell leukemia, also functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA." | 5.56 | Cladribine Induces ATF4 Mediated Apoptosis and Synergizes with SAHA in Diffuse Large B-Cell Lymphoma Cells. ( Gao, X; Jiao, J; Li, Z; Liu, M; Qin, Y; Sang, W; Song, X; Sun, C; Sun, X; Tian, Y; Xu, K; Xu, L; Yan, D; Yang, P; Zeng, L; Zhu, F, 2020) |
| "A panel of rituximab-chemotherapy-sensitive (RSCL) and rituximab-chemotherapy-resistant cell lines (RRCL) and primary tumor cells isolated from relapsed/refractory B cell lymphoma patients were exposed to escalating doses of vorinostat." | 3.83 | Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. ( Czuczman, MS; Gu, JJ; Guo, Y; Hernandez-Ilizaliturri, FJ; Mavis, C; Xue, K; Zhang, Q, 2016) |
| "Interactions between histone deacetylase inhibitors (HDACIs) and the novel proteasome inhibitor carfilzomib (CFZ) were investigated in GC- and activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) cells." | 3.76 | The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. ( Dasmahapatra, G; Dent, P; Fisher, RI; Friedberg, J; Grant, S; Kramer, L; Lembersky, D, 2010) |
| " S0806 was a single arm phase I/II trial of vorinostat given at 400 mg po daily on days 1-9 (subsequently amended to days 1-5 due to toxicity), combined with R-CHOP given on day 3 of a 21-day cycle for 8 cycles, with primary phase II endpoint of 2-year progression free survival (PFS)." | 2.87 | A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. ( Bane, CL; Barr, PM; Fisher, RI; Friedberg, JW; LeBlanc, M; Li, H; Persky, DO; Popplewell, LL; Rimsza, LM; Smith, SM; Von Gehr, A, 2018) |
| "Vorinostat (400 mg) was administered orally on days 1 to 5 and 8 to 12 before bortezomib (1." | 2.87 | A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. ( Badros, AZ; Baz, R; Bose, P; Coppola, D; Flowers, C; Grant, S; Holkova, B; Kimball, A; Kmieciak, M; Lin, HY; Morgan, D; Parekh, S; Perkins, EB; Reich, RR; Richards, KL; Roberts, JD; Ruan, J; Sankala, H; Shafer, D; Shea, T; Shrader, E; Sokol, L; Strair, R; Sullivan, D; Tombes, MB; Yazbeck, V; Zhao, X, 2018) |
| "The standard treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in frail elderly patients has not been established." | 2.80 | Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation. ( Cella, D; Drullinsky, PR; Elstrom, R; Gerecitano, JF; Hamilton, AM; Hamlin, PA; Lia Palomba, M; Matasar, MJ; Noy, A; Straus, DJ; Wegner, B; Wortman, K; Zelenetz, AD, 2015) |
| "Vorinostat was given at 200 mg/day to 1000 mg/day (days -8 to -3)." | 2.80 | Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. ( Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hagemeister, F; Hosing, C; Jones, RB; Liu, Y; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC, 2015) |
| "Vorinostat was well tolerated at 300 mg b." | 2.73 | Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. ( Cheson, BD; Coiffier, B; Crump, M; Frankel, SR; Jacobsen, ED; Randolph, SS; Ricker, JL; Sun, L; Xie, H, 2008) |
| "Cladribine is a purine nucleoside analog used to treat B-cell chronic lymphocytic leukemia and hairy cell leukemia, also functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA." | 1.56 | Cladribine Induces ATF4 Mediated Apoptosis and Synergizes with SAHA in Diffuse Large B-Cell Lymphoma Cells. ( Gao, X; Jiao, J; Li, Z; Liu, M; Qin, Y; Sang, W; Song, X; Sun, C; Sun, X; Tian, Y; Xu, K; Xu, L; Yan, D; Yang, P; Zeng, L; Zhu, F, 2020) |
| " Here, we report in vivo data for OTX015 in combination with the histone deacetylase inhibitor vorinostat, the Bruton's tyrosine kinase inhibitor ibrutinib, the anti-CD20 monoclonal antibody rituximab, and the mTOR inhibitor everolimus in a diffuse large B cell lymphoma model." | 1.43 | Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma. ( Bernasconi, E; Bertoni, F; Cascione, L; Cvitkovic, E; Gaudio, E; Odore, E; Ponzoni, M; Rezai, K; Rinaldi, A; Riveiro, E; Stathis, A; Tarantelli, C; Zucca, E, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 11 (64.71) | 24.3611 |
| 2020's | 4 (23.53) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, K | 1 |
| Huang, L | 1 |
| Lai, F | 1 |
| Lin, S | 1 |
| Tian, H | 1 |
| Wu, D | 1 |
| Chen, X | 1 |
| Xu, H | 1 |
| Wang, X | 2 |
| Hong, Y | 1 |
| Meng, S | 1 |
| Gong, W | 1 |
| Ren, T | 1 |
| Zhang, T | 1 |
| Liu, X | 1 |
| Li, L | 1 |
| Qiu, L | 1 |
| Qian, Z | 1 |
| Zhou, S | 1 |
| Zhao, M | 1 |
| Zhai, Q | 1 |
| Meng, B | 1 |
| Ren, X | 1 |
| Zhang, H | 1 |
| Alkhaldi, H | 1 |
| Reinhardt, A | 1 |
| Barnett, M | 1 |
| Kundu, S | 1 |
| Hosing, C | 2 |
| Ramdial, J | 1 |
| Saini, N | 1 |
| Srour, S | 1 |
| Alousi, A | 2 |
| Kebriaei, P | 1 |
| Popat, U | 2 |
| Qazilbash, M | 2 |
| Champlin, R | 2 |
| Shpall, EJ | 2 |
| Gulbis, A | 2 |
| Shigle, TL | 1 |
| Dabaja, B | 2 |
| Pinnix, C | 2 |
| Ahmed, S | 2 |
| Steiner, R | 1 |
| Andersson, BS | 2 |
| Nieto, Y | 2 |
| Xu, L | 1 |
| Jiao, J | 1 |
| Sun, X | 1 |
| Sang, W | 1 |
| Gao, X | 1 |
| Yang, P | 1 |
| Yan, D | 1 |
| Song, X | 1 |
| Sun, C | 1 |
| Liu, M | 1 |
| Qin, Y | 1 |
| Tian, Y | 1 |
| Zhu, F | 1 |
| Zeng, L | 1 |
| Li, Z | 1 |
| Xu, K | 1 |
| Persky, DO | 1 |
| Li, H | 1 |
| Rimsza, LM | 1 |
| Barr, PM | 1 |
| Popplewell, LL | 1 |
| Bane, CL | 1 |
| Von Gehr, A | 1 |
| LeBlanc, M | 1 |
| Fisher, RI | 2 |
| Smith, SM | 1 |
| Friedberg, JW | 1 |
| Yazbeck, V | 1 |
| Shafer, D | 1 |
| Perkins, EB | 1 |
| Coppola, D | 1 |
| Sokol, L | 1 |
| Richards, KL | 1 |
| Shea, T | 1 |
| Ruan, J | 2 |
| Parekh, S | 1 |
| Strair, R | 1 |
| Flowers, C | 1 |
| Morgan, D | 1 |
| Kmieciak, M | 1 |
| Bose, P | 1 |
| Kimball, A | 1 |
| Badros, AZ | 1 |
| Baz, R | 1 |
| Lin, HY | 1 |
| Zhao, X | 1 |
| Reich, RR | 1 |
| Tombes, MB | 1 |
| Shrader, E | 1 |
| Sankala, H | 1 |
| Roberts, JD | 1 |
| Sullivan, D | 1 |
| Grant, S | 2 |
| Holkova, B | 1 |
| Straus, DJ | 1 |
| Hamlin, PA | 1 |
| Matasar, MJ | 1 |
| Lia Palomba, M | 1 |
| Drullinsky, PR | 1 |
| Zelenetz, AD | 1 |
| Gerecitano, JF | 1 |
| Noy, A | 1 |
| Hamilton, AM | 1 |
| Elstrom, R | 3 |
| Wegner, B | 1 |
| Wortman, K | 1 |
| Cella, D | 1 |
| Valdez, BC | 1 |
| Thall, PF | 1 |
| Jones, RB | 1 |
| Anderlini, P | 1 |
| Shah, N | 1 |
| Bashir, Q | 1 |
| Liu, Y | 1 |
| Oki, Y | 1 |
| Hagemeister, F | 1 |
| Fanale, M | 1 |
| Fernández-Rodríguez, C | 1 |
| Salar, A | 1 |
| Navarro, A | 1 |
| Gimeno, E | 1 |
| Pairet, S | 1 |
| Camacho, L | 1 |
| Ferraro, M | 1 |
| Serrano, S | 1 |
| Besses, C | 1 |
| Bellosillo, B | 1 |
| Sanchez-Gonzalez, B | 1 |
| Xue, K | 1 |
| Gu, JJ | 1 |
| Zhang, Q | 1 |
| Mavis, C | 1 |
| Hernandez-Ilizaliturri, FJ | 1 |
| Czuczman, MS | 1 |
| Guo, Y | 1 |
| Dupéré-Richer, D | 1 |
| Kinal, M | 1 |
| Pettersson, F | 1 |
| Emond, A | 1 |
| Calvo-Vidal, MN | 1 |
| Nichol, JN | 1 |
| Guilbert, C | 1 |
| Plourde, D | 1 |
| Klein Oros, K | 1 |
| Nielsen, TH | 1 |
| Ezponda, T | 1 |
| Licht, JD | 1 |
| Johnson, NA | 1 |
| Assouline, S | 1 |
| Cerchietti, L | 2 |
| Miller, WH | 1 |
| Mann, KK | 1 |
| Pera, B | 1 |
| Tang, T | 1 |
| Marullo, R | 1 |
| Yang, SN | 1 |
| Ahn, H | 1 |
| Patel, J | 1 |
| Furman, R | 1 |
| Leonard, J | 1 |
| Martin, P | 2 |
| Gaudio, E | 1 |
| Tarantelli, C | 1 |
| Ponzoni, M | 1 |
| Odore, E | 1 |
| Rezai, K | 1 |
| Bernasconi, E | 1 |
| Cascione, L | 1 |
| Rinaldi, A | 1 |
| Stathis, A | 1 |
| Riveiro, E | 1 |
| Cvitkovic, E | 1 |
| Zucca, E | 1 |
| Bertoni, F | 1 |
| Leonard, JP | 1 |
| Barrientos, J | 1 |
| Dasmahapatra, G | 1 |
| Lembersky, D | 1 |
| Kramer, L | 1 |
| Friedberg, J | 1 |
| Dent, P | 1 |
| Smeltzer, JP | 1 |
| Viswanatha, DS | 1 |
| Habermann, TM | 1 |
| Patnaik, MM | 1 |
| Crump, M | 1 |
| Coiffier, B | 1 |
| Jacobsen, ED | 1 |
| Sun, L | 1 |
| Ricker, JL | 1 |
| Xie, H | 1 |
| Frankel, SR | 1 |
| Randolph, SS | 1 |
| Cheson, BD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Vorinostat (SAHA) Combined With High-Dose Gemcitabine, Busulfan, and Melphalan With Autologous Hematopoietic Cell Support for Patients With Relapsed or Refractory Lymphoid Malignancies[NCT01421173] | Phase 1 | 78 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| A Phase II Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)[NCT00097929] | Phase 2 | 18 participants (Actual) | Interventional | 2005-05-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for vorinostat and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Targeted treatment and new agents in diffuse large B-cell lymphoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bor | 2008 |
6 trials available for vorinostat and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cy | 2018 |
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Drug Res | 2018 |
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Dr | 2015 |
Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug | 2008 |
10 other studies available for vorinostat and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
Topics: Animals; Apoptosis; Cell Line, Tumor; Histone Deacetylase Inhibitors; Humans; Lymphoma, Large B-Cell | 2022 |
A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2022 |
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Huma | 2023 |
Cladribine Induces ATF4 Mediated Apoptosis and Synergizes with SAHA in Diffuse Large B-Cell Lymphoma Cells.
Topics: Activating Transcription Factor 4; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell | 2020 |
Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Su | 2016 |
Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Burkitt Lymphoma; Cell Growth Processes; | 2016 |
Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.
Topics: Animals; Antineoplastic Agents; Boron Compounds; Bortezomib; Drug Resistance, Neoplasm; Gene Express | 2017 |
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Topics: Acetanilides; Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Antineop | 2016 |
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Chymotrypsin; DNA | 2010 |
Secondary Epstein-Barr virus associated lymphoproliferative disorder developing in a patient with angioimmunoblastic T cell lymphoma on vorinostat.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Epstein-Barr Virus Infections; Female; Humans; Hydro | 2012 |